News at cGMP Contract Manufacturing Company, Cytovance Biologics
 
 

News

Cytovance Biologics Announces Launch of Keystone Expression System™ - 10/21/2014
Cytovance Biologics, a leading full-service contract manufacturing organization ("CMO") of mammalian and microbial biologics with 10 years' industry experience, has announced the launch of its new Microbial expression platform, which is named The Keystone Expression System™.  [More]

Cytovance Biologics Strengthens Quality Team - 08/12/2014 
Cytovance Biologics, a leading full-service contract manufacturing organization (“CMO”) of mammalian and microbial biologics, welcomes Mark Ambrose, Ph.D., as Senior Director of Quality Systems and Compliance and Anne Garstka as Director of Commercial Compliance.  [More

Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences - 06/23/2014 
Cytovance Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, announces successful completion of GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10).  [More

Cytovance Biologics experts contribute to Elsevier’s biotech entrepreneur publication - 06/10/2014 
Cytovance Biologics manufacturing experts recently contributed to Elsevier’s latest publication, Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies, an authoritative guide to biotechnology enterprise and entrepreneurship that supports the international community in training the biotechnology leaders of tomorrow.  [More

Cytovance Biologics' Jesse McCool, Ph.D. to present at Manubio's Annual BioManufacturing and Process Innovation Summit - 05/28/2014 
Oklahoma City, OK -- Cytovance Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announces that Sr. Vice President of R&D Services, Jesse McCool, Ph.D., will speak at the Annual Manubio Summit in Boston.  His presentation will focus on  will focus on Leveraging Innovation to Achieve Manufacturing Excellence Across Mammalian and Microbial Biologics Processes.  [More

Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 - 05/06/2014
Oklahoma City, OK -- Cytovance Biologics, Inc., a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical stage biopharmaceutical company.  [More

Cytovance Biologics' Jonathan Mitschelen, Ph.D. to co-present at 10th Annual PEGS Conference - 04/22/2014
Oklahoma City, OK -- Cytovance Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announces that Vice President of Upstream Process Development, Jonathan Mitschelen, Ph.D., will speak at the 10th Annual PEGS Conference in Boston.  The case study presentation will focus on the Identification and Risk Mitigation of a Critical Process Parameter during Antibody Process Scale-up.  [More

Cytovance Biologics, Inc. and Precision Biologics, Inc. Announce Extended cGMP Manufacturing Agreement for NEO-102 Drug Product - 03/25/2014
Oklahoma City, OK -- Cytovance Biologics, Inc., a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, is extending its manufacturing agreement with Precision Biologics, Inc., a Texas-based clinical stage biopharmaceutical company.  [More

Cytovance Biologics, Inc. and Pamlico Biopharma, Inc. Announce Development and cGMP Manufacturing Agreement - 02/18/2014
Oklahoma City, OK -- Cytovance Biologics, Inc., a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces that they have entered into a development and manufacturing agreement with Pamlico Biopharma, Inc., an Oklahoma City-based clinical stage bio-pharmaceutical company.  [More]

Cytovance Biologics breaks ground on GMP Warehouse and Manufacturing Operations facility - 01/28/2014
Cytovance Biologics broke ground on an expansion facility to contain both manufacturing operations and GMP warehousing. The multi-million dollar capital investment project is being built by Capstone Construction and is expected to be completed by June 2014.  [More

Cytovance Biologics sets 2014 exhibit schedule - 12/11/2013
Cytovance Biologics announces its preliminary exhibit schedule for 2014 where representatives will be available to discuss how Cytovance can support your biologics outsourcing needs. [More

Cytovance Biologics experts contribute to Parenteral Drug Association's Pharmaceutical Outsourcing publication - 11/19/2013
Cytovance Biologics is a proud contributor to the Parenteral Drug Association’s latest publication, Pharmaceutical Outsourcing: Quality Management and Project Delivery. [More

Cytovance Biologics announces Jesse McCool as Vice President of Microbial Services - 11/05/2013
Oklahoma City, OK -- Cytovance Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces Jesse McCool as Vice President of Microbial Services. [More]

Cytovance Biologics, Inc. and Translational Sciences, Inc. Announce Manufacturing Agreement for Stromab - 10/01/2013
Oklahoma City, OK -- Cytovance Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, announces that they have entered into a manufacturing agreement with Translational Sciences, Inc., a Memphis, Tennessee-based clinical stage biopharmaceutical company. [More]

Cytovance Biologics ranked 32nd on Oklahoma City’s Metro 50 - 09/24/2013
Oklahoma City, OK -- Cytovance Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, was named the 32nd fastest-growing private company in Oklahoma City at the 2013 Metro 50 Awards hosted recently by the Greater Oklahoma City Chamber of Commerce. [More

Cytovance Biologics to receive Metro 50 Award - 08/20/2013
Oklahoma City, OK -- Cytovance Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, has recently been named as one of Oklahoma City’s fastest growing private companies. [More]

Cytovance CSO Jeffrey Su, Ph.D., to present at 5th Annual BioProcess International China Conference - 07/18/2013
Oklahoma City, OK -- Cytovance® Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announces that CSO Jeffrey Su, Ph.D., will speak at the 5th Annual BioProcess International China Conference in Shanghai, China in August 2013.  The presentation title is Biosimilars: Challenges and Solutions. [More

Cytovance® Biologics extends a 20% Conference Savings for BioProcess International Attendees - 07/18/2013
Oklahoma City, OK -- Cytovance® Biologics is attending the BioProcess International Conference in Boston, MA, September 16-19 and we invite you to join us for this exciting event! With this invite offer you are eligible to receive a special 20%* exhibitor-colleague registration discount to attend as our preferred guest or a free exhibit hall and keynote pass when you register with priority code BP13SPEX31. [More]

Cytovance® Biologics to Expand Microbial Manufacturing - 04/16/2013
Oklahoma City, OK -- Cytovance® Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, announces the planned expansion of its microbial manufacturing capabilities. In addition to its current 100L Fermenter, Cytovance recently acquired a second 100L and a 1000L Fermenter. [More

Cytovance CSO Jeffrey Su, Ph.D., to present at 5th Annual International Conference of Antibodies in China - 02/12/2013
Oklahoma City, OK -- Cytovance® Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announces that CSO Jeffrey Su, Ph.D., will speak at the 5th Annual International Conference of Antibodies in Hangzhou, China in March 2013.  The presentation title is Biosimilars: Challenges and Solutions. [More

Cytovance® Biologics to Expand Production Capabilities in 2013 - 01/29/2013
Oklahoma City, OK -- Cytovance® Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announced today that it will expand its current mammalian production capabilities to include a 1,000L SUB bioreactor, a 5,000L stainless steel bioreactor and an automated fill/finish line. [More]

Cytovance® Biologics welcomes Maria Lopez as Vice President of Quality - 01/23/2013
Oklahoma City, Okla. -- Cytovance® Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, welcomes Maria Lopez as the Vice President of Quality. [More]

Shannon Goodson named President of the South Central ISPE Chapter - 12/11/2012

Cytovance® Biologics, Inc. Announces Manufacturing Agreement with Selexys Pharmaceuticals Corp. for Phase II Production of SelG1 - 11/13/2012

Cytovance® Biologics, Inc. Awarded Biopharmaceutical Development and Manufacturing Contract by Fountain BioPharma, Inc. - 10/31/2012

Cytovance® Biologics scores improved Customer Perception ratings - 10/09/2012

Selexys Pharmaceuticals wins investment, Cytovance Biologics continues as contract manufacturer - 9/19/2012

Cytovance® Biologics receives 2012 CMO Leadership Award for Reliability - 9/18/2012

Cytovance® Biologics Announces Don Wuchterl as Senior Vice President of Manufacturing Operations - 07/30/12

Cytovance® Biologics Announces New Corporate Logo and Website - 07/02/12

Darren Head interviewed in GEN's "Changing Landscape for Contract Manufacturers" - 07/01/12

BiologicsMD, Inc. Awards Manufacturing Contract to Cytovance Biologics, Inc. to Expand Development of Breakthrough Osteoporosis Medication - 06/12/12

Cytovance® Biologics Names Martin LeBlanc to Board of Directors - 05/08/12

Cytovance® Biologics Receives 2012 Best of Oklahoma City Award - 03/23/12

Cytovance® Biologics Strengthens Management Team- 03/15/12

Cytovance® Biologics Manufacturing Capacity Grows- 01/27/12

Cytovance® Biologics Hires Valerie McDonnell as Vice President of Sales and Business Development- 01/26/12

Cytovance® Biologics secures a staged $22.5 million equity investment- 03/15/11

Cytovance® Biologics Awarded Biopharmaceutical Development, Manufacturing Contract by Selexys Pharmaceutical Corporation - 04/27/10

DASGIP Spotlight: Fed Batch Process Scale Up from 0.6 to 100L - 03/18/10